Mercer Global Advisors
SNDX icon

Mercer Global Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Mercer Global Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$552K Buy
23,637
+5,832
+33% +$127K ﹤0.01% 1915
2025
Q4 		$374K Buy
+17,805
New +$311K ﹤0.01% 2071

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Mercer Global Advisors's SNDX Position: Q1 2026 in Review

Mercer Global Advisors increased its Syndax Pharmaceuticals (SNDX) stake by 33% in Q1 2026, buying an estimated $127K and bringing the position to 23,637 shares worth $552K. The position accounts for ﹤0.01% of the portfolio, ranked #1915.

Mercer Global Advisors first reported a position in SNDX in Q4 2025 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Mercer Global Advisors held 23,637 shares of Syndax Pharmaceuticals worth $552K as of Q1 2026.
  • Mercer Global Advisors bought 5,832 Syndax Pharmaceuticals shares in Q1 2026, an estimated $127K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #1915 holding.
  • Mercer Global Advisors first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.